Here we pre-treated breast cancer cell lines (MDA-MB-231 and BT-474) with 20 μM of MK-571, a specific ABCC1 inhibitor, for 1 hour, followed by treatment with 0.5 μM rhodamine 123, a standard substrate for retention studies [23]. This evidence concerns the gene ABCC1 and breast carcinoma.